Onyx Therapeutics, Inc. v. Dr. Reddy's Laboratories, Inc.
1:16-cv-01011
Overview
Parties
Defendant
Dr. Reddy's Laboratories, Ltd. Operating Company
Represented By
2 Attorneys ListedPotter Anderson & Corroon, LLP
1313 N. Market St., Hercules Plaza, 6th Flr., P.O. Box 951
Potter Anderson & Corroon, LLP
1313 N. Market St., Hercules Plaza, 6th Flr., P.O. Box 951
Dr. Reddy's Laboratories, Inc. Operating Company
Represented By
4 Attorneys ListedPotter Anderson & Corroon, LLP
1313 N. Market St., Hercules Plaza, 6th Flr., P.O. Box 951
Potter Anderson & Corroon, LLP
1313 N. Market St., Hercules Plaza, 6th Flr., P.O. Box 951
Plaintiff
Onyx Therapeutics, Inc. Operating Company
Represented By
6 Attorneys ListedO'Melveny & Myers LLP
7 Times Square, Times Square Tower, New York, NY 10036
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 3 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | US 7,737,112 B2 Asserted | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 63,436,604 P | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 65,593,005 P | US Continuation / Sibling | View Official Patent → |
Onyx Therapeutics, Inc. v. InnoPharma Inc.
Onyx Therapeutics, Inc. v. MSN Pharmaceuticals, Inc.
Onyx Therapeutics, Inc. v. Sagent Pharmaceuticals, Inc.
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US7737112
Composition for enzyme inhibition
|
Filed: 2005-12-07
Issued: 2010-06-15
|
Active (1.1 yrs remaining)
+742d PTA
Expires: 2027-12-19
|
Patent Enforceability & Injunction Risk Assessment
Active Threat β Patent is within enforceable statutory term. Patentee retains legal standing to seek permanent injunctive relief and exclusion orders.
High PTA (+742 days) / Cellect Scrutiny β Over 742 days of PTA awarded. Susceptible to In re Cellect double patenting invalidation if continuation patents in the same family expire earlier.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
3
Dispositive
0
Granted
0
Denied
0
Pending / Review
3
Motions by Category
Key Dispositive Motions & Rulings